Podcast: AAIC 2025 highlights and the latest trends in Alzheimer's disease IVDs
A key theme among many presentations was the use of ALZpath's pTau217 antibody.
The biomarker featured in seven presentations and 30 posters. A presentation from Roche shared new real-world data confirming that its blood-based biomarker, Elecsys pTau217, provided comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology.
Medical Device Network sat down with Selena Yu, senior medical analyst at GlobalData, to learn more about the key IVD news from this year's AAIC and the direction in which Alzheimer's disease research and development is currently headed.
You can listen to the podcast below:
Este contenido insertado no está disponible en tu región.
"Podcast: AAIC 2025 highlights and the latest trends in Alzheimer's disease IVDs" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
23 minutes ago
- Gizmodo
How Alien Life Could Exist Without Water
The search for alien life usually hinges on finding the same conditions that sustain life on Earth. But what if aliens don't need the same things that we need to survive? A new proposal tackles this question for water—arguably one of the most important factors in the search for alien life. Intriguing new research from MIT proposes that liquids are what's important for extraterrestrial habitability, and not just water. The new research specifically focuses on ionic fluids—substances that planetary scientists believe could form on the surfaces of rocky planets and moons. Ionic liquids are highly tolerant to high temperatures and low pressures, allowing them to remain in a stable liquid state that's potentially friendly to biomolecules. If confirmed, the proposal, published August 11 in Proceedings of the National Academy of Sciences, would dramatically expand what's considered the 'habitable zone' among known exoplanets. By current standards, the habitable zone is defined as the band within planetary systems in which liquid water can remain stable on the surface. When it comes to life, we're understandably biased towards water; all life as we know it depends on it. 'We consider water to be required for life because that is what's needed for Earth life,' Rachana Agrawal, study lead author and a postdoctoral researcher at MIT, told MIT News. 'But if we look at a more general definition, we see that what we need is a liquid in which metabolism for life can take place.' Originally, the researchers were studying the toxic, gassy atmosphere of Venus and whether such conditions could support extraterrestrial life. The planet is shrouded in clouds of sulfuric acid, a common byproduct of volcanic activity on Earth and, presumably, on other rocky planets. While experimenting with different ways to extract organic compounds from sulfuric acid, the team noticed that each time, 'a stubborn layer of liquid always remained,' they explained. 'From there, we took the leap of imagination of what this could mean,' Agrawal said. 'Sulfuric acid is found on Earth from volcanoes, and organic compounds have been found on asteroids and other planetary bodies. So, this led us to wonder if ionic liquids could potentially form and exist naturally on exoplanets.' For the study, the researchers explored how ionic liquids could form naturally. (Earth's ionic liquids are largely synthesized for industrial purposes; the only natural instance is the venom mixture from two very specific species of ants). They mixed various nitrogen-containing organic compounds with sulfuric acid on basalt rock, a common geological feature of rocky planets. This reaction occurred under the hot, low-pressure conditions resembling the weather at Venus or other rocky planets. They found that ionic liquid emerged from these experiments at temperatures up to 356 degrees Fahrenheit (180 degrees Celsius) and also at extremely low pressures. 'We were just astonished that the ionic liquid forms under so many different conditions,' Sara Seager, study co-author and an astrophysicist at MIT, told MIT News. The results also demonstrate the extraordinary persistence of ionic liquids compared to water, Seager explained. If 'pockets' of ionic liquid could remain on a planet's surface for millennia, they'd be the 'small oases for simple forms of ionic-liquid-based life.' 'We just opened up a Pandora's box of new research,' Seager added. It's wholly reasonable to begin the search for alien life using Earth and Earth-based life as our starting point. But when we consider something that could contradict these baseline assumptions, that's when the most provocative, groundbreaking initiatives come to life.
Yahoo
44 minutes ago
- Yahoo
5 Pew-Stewart Scholars Selected to Pursue Pioneering Cancer Research
PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2025 class of the Pew-Stewart Scholars Program for Cancer Research. The five early-career scientists will each receive four-year grants to conduct innovative research projects spanning cancer development, diagnosis, and treatment. This is the 12th year the Alexander and Margaret Stewart Trust has partnered with Pew to support promising cancer researchers. "Cancer continues to have a profound impact on the lives of so many, but scientific advancements hold hope for improving how we diagnose and treat the disease," said Donna Frisby-Greenwood, senior vice president for Philadelphia and scientific advancement at The Pew Charitable Trusts. "These researchers are primed to lead these discoveries, and Pew is honored to support their work." This group of scientists will explore a range of pressing topics, including uncovering the mechanisms behind some of the most complex cancer types and exploring new drug targets and opportunities for more effective immunotherapies. "Pew-Stewart scholars are leading transformative advances in cancer research, and these five outstanding investigators exemplify that spirit," said Helen Piwnica-Worms, Ph.D., chair of the Pew-Stewart program's national advisory committee. "We are proud to welcome them to the Pew-Stewart community and look forward to the impact their research will have on improving cancer treatment and patient outcomes." The 2025 Pew-Stewart Scholars for Cancer Research are: Iain Clark, of California, BerkeleyDr. Clark will examine the genetic underpinnings of mixed phenotype acute leukemia, one of the most lethal and poorly understood forms of the disease. Ryan Flynn, M.D., Children's HospitalDr. Flynn will study how molecules such as RNAs and the proteins they bind influence cellular processes in the context of human disease, and their potential as targets for new cancer therapies. Javier Garcia-Bermudez, Medical Center Research Institute at UT SouthwesternDr. Garcia-Bermudez will explore how fats derived from dietary sources, primarily those from lipoproteins, promote tumor growth, metastasis, and therapy resistance. Anna Nam, Cornell MedicineDr. Nam will investigate the genetic determinants that influence the clinical manifestations of Hodgkin lymphoma and non-Hodgkin lymphoma, two types of blood cancer. Bingfei Yu, of Southern CaliforniaDr. Yu will examine how T cells are crucial in shaping the immune system to recognize and target threats to develop precision immunotherapies for cancer and other diseases. Founded in 1948, The Pew Charitable Trusts uses data to make a difference. Pew addresses the challenges of a changing world by illuminating issues, creating common ground, and advancing ambitious projects that lead to tangible progress. Erin Davis, 202-540-6677, edavis@ View original content: SOURCE The Pew Charitable Trusts
Bloomberg
an hour ago
- Bloomberg
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
If Novo Nordisk A/S 's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.'
